{
    "ticker": "SANG",
    "name": "Sangamo Therapeutics, Inc.",
    "description": "Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicine to transform the lives of patients with serious diseases. Founded in 1995, the company specializes in gene therapy, genome editing, and gene regulation technologies. Sangamo's innovative platform includes zinc finger protein (ZFP) technology, which allows for precise modifications of the genome to address genetic disorders, cancer, and other diseases. The company\u2019s lead programs are centered around hemophilia, lysosomal storage disorders, and neurodegenerative diseases, with ongoing clinical trials aimed at demonstrating the safety and efficacy of its therapies. Sangamo is committed to pioneering advancements in gene therapy and editing to provide transformative treatment options for patients. Collaborating with leading pharmaceutical companies enhances its ability to bring these cutting-edge therapies to market. With a strong focus on research and development, Sangamo strives to lead the way in genomic medicine and redefine the landscape of therapeutic options for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Richmond, California, USA",
    "founded": "1995",
    "website": "https://www.sangamo.com",
    "ceo": "Edward Lanphier",
    "social_media": {
        "twitter": "https://twitter.com/SangamoTx",
        "linkedin": "https://www.linkedin.com/company/sangamo-therapeutics/"
    },
    "investor_relations": "https://investors.sangamo.com",
    "key_executives": [
        {
            "name": "Edward Lanphier",
            "position": "CEO"
        },
        {
            "name": "Kathy High",
            "position": "President and Chief Scientific Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapy",
            "products": [
                "SB-525 (Hemophilia A)",
                "ST-400 (Beta-Thalassemia)",
                "TX200 (Kidney Transplant)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sangamo Therapeutics, Inc. | Genomic Medicine and Gene Therapy",
        "meta_description": "Explore Sangamo Therapeutics, Inc., a leader in genomic medicine. Discover our innovative gene therapy technologies and commitment to transforming patient lives.",
        "keywords": [
            "Sangamo",
            "Gene Therapy",
            "Genomic Medicine",
            "Zinc Finger Technology",
            "Hemophilia",
            "Beta-Thalassemia"
        ]
    },
    "faq": [
        {
            "question": "What does Sangamo Therapeutics do?",
            "answer": "Sangamo Therapeutics focuses on developing genomic medicine and gene therapies for serious diseases."
        },
        {
            "question": "Who is the CEO of Sangamo?",
            "answer": "Edward Lanphier is the CEO of Sangamo Therapeutics, Inc."
        },
        {
            "question": "Where is Sangamo headquartered?",
            "answer": "Sangamo is headquartered in Richmond, California, USA."
        },
        {
            "question": "What are Sangamo's main products?",
            "answer": "Sangamo's main products include SB-525 for Hemophilia A and ST-400 for Beta-Thalassemia."
        },
        {
            "question": "When was Sangamo founded?",
            "answer": "Sangamo was founded in 1995."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGMO",
        "ALNY"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "VRTX"
    ]
}